Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | PLN 624,413 | PLN 722,525 | PLN 647,364 | PLN 890,126 |
| - Cash | PLN 83,258 | PLN 102,566 | PLN 144,212 | PLN 160,073 |
| + Debt | PLN 70,541 | PLN 68,819 | PLN 74,235 | PLN 75,514 |
| Enterprise Value | PLN 611,696 | PLN 688,778 | PLN 577,387 | PLN 805,567 |
| Revenue | PLN 14,918 | PLN 12,403 | PLN 16,933 | PLN 25,545 |
| % Growth | 20.3% | -26.8% | -33.7% | – |
| Gross Profit | -PLN 28,558 | PLN 9,026 | PLN 13,225 | PLN 19,685 |
| % Margin | -191.4% | 72.8% | 78.1% | 77.1% |
| EBITDA | -PLN 19,790 | -PLN 28,375 | -PLN 21,184 | -PLN 30,689 |
| % Margin | -132.7% | -228.8% | -125.1% | -120.1% |
| Net Income | -PLN 24,707 | -PLN 33,658 | -PLN 25,276 | -PLN 35,052 |
| % Margin | -165.6% | -271.4% | -149.3% | -137.2% |
| EPS Diluted | -1.1 | -1.5 | -1.1 | -1.52 |
| % Growth | 26.7% | -36.4% | 27.6% | – |
| Operating Cash Flow | -PLN 17,418 | -PLN 24,407 | -PLN 44,183 | -PLN 27,935 |
| Capital Expenditures | -PLN 1,483 | -PLN 422 | -PLN 746 | PLN 230 |
| Free Cash Flow | -PLN 18,901 | -PLN 24,829 | -PLN 44,929 | -PLN 27,705 |